Meeting the Challenge: Transforming Patient Care in sHTG and FCS With Novel RNA-Based Therapies

Deepen your understanding of the pathophysiology of severe hypertriglyceridemia (sHTG) and familial chylomicronemia (FCS), along with the challenges patients face in diagnosis and management. This program will explore the new role RNA-based therapies play in improving patient outcomes, through an expert-written ClinicalThought, on-demand webcast, and downloadable slides.

Share

Program Content

Activities

Transforming sHTG and FCS care
Meeting the Challenge: Transforming Patient Care in sHTG and FCS With Novel RNA-Based Therapies
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 24, 2025

Expires: March 23, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by a grant from Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.